0.00
-12.94%
Close of 5 Nov 2026, in USD
About BioAdaptives
From its filings with the US Securities and Exchange Commission
BioAdaptives is based in Las Vegas, Nevada and is incorporated in Delaware. Its shares trade on OTC under the ticker BDPT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $18,278 and a net loss of $1.6m. At that date it held total assets of $225,901 and shareholders' equity of −$2.1m.
BioAdaptives, Inc., ("BioAdaptives," the "Company," "we" or "us") was incorporated in the State of Delaware on April 19, 2013, as APEX 8 Inc. From inception through October 21, 2013, the Company was in the developmental stage and conducted virtually no business operations, other than organizational activities and preparation of a registration statement on Form 10-12g (the "Registration Statement"), which was filed with the U.S. Securities and Exchange Commission on May 3, 2013. On June 11, 2013, the SEC staff informed the Company that it had no further comments.
On January 10, 2014, the SEC notified the Company that the registration statement was effective and on July 9, 2014, the Company’s shares commenced trading in the Over-the-Counter market under the trading symbol BDPT.
On March 31, 2017, the Company filed a Form 15-15D with the SEC, terminating its status as an SEC-reporting company; it was current in its Continuous Disclosure obligations at that time. The Company continued to provide financial and other reports to shareholders and the public by means of the Alternative Reporting System operated by OTC Markets Group, Inc. Its shares continued to trade in the OTC market and it also continued to execute its business plan.
Quoted from its 10-K, filed 14 Apr 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 9 Jul 2014
- Employees
- 1
- Website
- bioadaptives.com ↗
- Head office
- 2620 REGATTA DRIVE, LAS VEGAS, NV, 89128
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. James KeenerChairman of the Board, Chief Executive Officer, since 2024
- Mr. Gimhana DissanayakeDirector
- Mr. Mark FrissoraDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company has a focused product portfolio including dietary supplements and nutraceuticals.
- It has a product agreement with Ferris Holding, Inc. for development and marketing.
- The company is developing multiple products including Equine Regen and Equine Regen Plus.
Weaknesses
- The company employs only one full-time employee.
- The company's sector and industry are listed as N/A, indicating unclear market positioning.
- The company's website is provided but no additional details about its operations are available.
Opportunities
- The company's products target health and wellness markets with potential for growth.
- The development of products for dogs could open new market segments.
- The company has intellectual property related to bioelectromagnetic availability of foods and beverages.
Threats
- The company's IPO date is from 2014, suggesting potential lack of recent market activity.
- The company's unverified source description may contain unreliable information.
- The company's small size and limited employee count could hinder growth and innovation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.